ACE2 gene expression was 2.868-fold higher in patients with COVID-19 (p = 0.000) (Table 1), and the expression was no longer restricted to cholangiocytes (as in the healthy liver) but extended to the liver parenchyma. The gene discussed is ACE2; the disease is COVID-19.